Dementia Clinical Trials

Find Dementia Clinical Trials Near You

Investigating Neurocognitive Disorders Epidemiology

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test, Other
Study Type: Observational
SUMMARY

This is a prospective cohort study with the main purpose of predicting progression neurocognitive disorders in Thai population. The main predictor variables to be evaluated are plasma phosphorylated tau (p-tau) level and cognitive test scores, which will be combined using statistical/computational modeling. Additionally, it seeks to evaluate biomarkers for diagnosing disease pathologies, understand their correlation with clinical outcomes, and explore the socioeconomic impact of neurocognitive disorders. The study invites both participants for biospecimen collection, structured interviews, and cognitive examinations and schedules follow-up visits annually or biennially.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Healthy Volunteers: t
View:

⁃ Demonstrate normal cognitive function within the expected range on objective cognitive tests.

⁃ Proficient in speaking and understanding Thai without the need for a translator to participate.

⁃ Display impaired/abnormal performance on objective cognitive tests.

⁃ Does not meet criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5).

⁃ Proficient in speaking and understanding Thai without the need for a translator to participate.

⁃ Display impaired/abnormal performance on objective cognitive tests.

⁃ Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.

⁃ Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring after the age of 65.

⁃ Proficient in speaking and understanding Thai without the need for a translator to participate.

• Display impaired/abnormal performance on objective cognitive tests.

• Meets criteria for dementia per NIA-AA (or major neurocognitive disorder per DSM-5), including dementia due to Alzheimer's disease or other causes.

• Begins to experience symptoms, identified by the physician as a part of dementia continuum, occurring before the age of 65.

• Proficient in speaking and understanding Thai without the need for a translator to participate.

Locations
Other Locations
Thailand
King Chulalongkorn Memorial Hospital
RECRUITING
Pathum Wan
Contact Information
Primary
Poosanu Thanapornsangsuth, M.D.
poosanu.t@chula.ac.th
+66 (0)2 2564000
Backup
Thanakit Pongpitakmetha, M.D.
thanakit.p@chula.ac.th
Time Frame
Start Date: 2023-08-24
Estimated Completion Date: 2035-08-24
Participants
Target number of participants: 990
Treatments
Cognitively healthy
This cohort includes participants with or without subjective complaints whose results of cognitive examination are normal. Participants will undergo clinical, epidemiological, and cognitive assessments, as well as biospecimen collection every two years, over an 8-year follow-up period.
Mild cognitive impairment
This cohort includes participants whose results of cognitive examination are abnormal but have not met the criteria for dementia. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of six years.
Late onset dementia
This cohort includes participants with dementia whose symptoms onset after the age of 65. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of two years.
Early onset dementia
This cohort includes participants with dementia whose symptoms onset before the age of 65. Participants will undergo annual clinical, epidemiological, and cognitive assessments, as well as biospecimen collection, for a duration of six years.
Related Therapeutic Areas
Sponsors
Collaborators: Health Systems Research Institute,Thailand
Leads: King Chulalongkorn Memorial Hospital

This content was sourced from clinicaltrials.gov